An observational study in Hepatic Encephalopathy, Hepatic Impairment and Hypothyroidism, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-01-16.
Sponsored by Assiut University · Observational
Liver plays an important role in the metabolism of thyroid hormones, as it is the most important organ in the peripheral conversion of tetraiodothyronine (T4) to triiodothyronine (T3) by Type 1 deiodinase.
In clinical terms, cirrhosis is described as are either "compensated" or "decompensated." Decompensation means cirrhosis complicated by one or more of the following features: jaundice, ascites, hepatic encephalopathy (HE), or bleeding varices. Ascites is the usual first sign. Hepatorenal syndrome, hyponatremia, and spontaneous bacterial peritonitis are also features of decompensation, but in these patients, ascites invariably occurs first. Compensated cirrhotic patients have none of these features.
The liver plays an important role in the metabolism of thyroid hormones, as it is the most important organ in the peripheral conversion of tetraiodothyronine (T4) to T3 by Type 1 deiodinase.
T4 and T3 regulate the basal metabolic rate of all cells, including hepatocytes, and thereby modulate hepatic function. The liver metabolizes the THS and regulates their systemic endocrine effects. Thyroid diseases may perturb liver function; liver disease modulates thyroid hormone metabolism; and a variety of systemic diseases affect both the organs.
225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.
This study's planned enrollment of 100 is close to the median of 100 across 58 observational studies indexed under Hepatic Encephalopathy.
Browse Hepatic Encephalopathy studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
all hepatic failutre patients who will be admitted to ICU will be enrolled, and throid function will be assessed. Groupingwil be done based upon throid function
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
throid fuction will be evaluated on admission of hepatic failure patients, and the hypothroid patients will be enroled in this group.
Diagnostic Test: hypothroidism
throid fuction will be evaluated on admission of hepatic failure patients, and the euothroid patients will be enroled in this group.
Diagnostic Test: euothyroid
throid fuction will be evaluated on admission of hepatic failure patients, and the hypothyroid patients will be enroled in this group.
throid fuction will be evaluated on admission of hepatic failure patients, and the euothyroid patients will be enroled in this group.
short termoutcome
mortality during hospitalstay
Time frame: (0 to 30 days)
complications
suchas renal affection, bleeding tendency ...etc
Time frame: (0 to 30 days)
Plan to share: No
Started Jan 2024 (actual). Primary completion is estimated for Apr 2024, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.